Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the
safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154
monotherapy as well as in combination with azacitidine or in combination with Azacitidine and
Venetoclax.